Novel Combination Product Captisol-Enabled® Budesonide + Azelastine HCl Provides Fast, Long-lasting Relief of Allergic Rhinitis Symptoms (Total Nasal Symptom Score (TNSS) and Individual Nasal Symptoms Scores (NSS)) in Ragweed Allergic Patients Studied in an Environmental Exposure Chamber (EEC) Model

2009 ◽  
Vol 123 (2) ◽  
pp. S130-S130 ◽  
Author(s):  
A. Salapatek ◽  
P. D'Angelo ◽  
M. Bates ◽  
D. Patel ◽  
P. Patel ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Symptom Score ◽  
Environmental Exposure ◽  
Nasal Symptom ◽  
Exposure Chamber ◽  
Combination Product ◽  
Nasal Symptoms ◽  
Total Nasal Symptom Score ◽  
Environmental Exposure Chamber

Onset of Action of Azelastine Nasal Spray Compared with Mometasone Nasal Spray and Placebo in Subjects with Seasonal Allergic Rhinitis Evaluated in an Environmental Exposure Chamber

2007 ◽  
Vol 21 (4) ◽  
pp. 499-503 ◽  
Author(s):  
Piyush Patel ◽  
Carrie D'Andrea ◽  
Harry J. Sacks
Keyword(s):  
Allergic Rhinitis ◽  
Environmental Exposure ◽  
Nasal Spray ◽  
Seasonal Allergic Rhinitis ◽  
Allergen Challenge ◽  
Nasal Symptom ◽  
Exposure Chamber ◽  
Onset Of Action ◽  
Environmental Exposure Chamber ◽  
Time Point

Background The objective of this study was to determine the onset of action of azelastine hydrochloride nasal spray compared with placebo and an intranasal steroid, mometasone furoate, in subjects with seasonal allergic rhinitis (SAR). Methods Subjects with a history of SAR and symptomatic while exposed to ragweed pollen in an environmental exposure chamber (EEC) were randomized to azelastine nasal spray (n = 150), mometasone nasal spray (n = 150), or placebo (n = 150) and recorded total nasal symptom scores (TNSS), consisting of sneezing, nasal pruritus, rhinorrhea, and congestion, during an 8-hour study period. Results Azelastine nasal spray showed a statistically significant improvement in the TNSS at 15 minutes compared with placebo. The effect was durable at each time point during the 8-hour study. Azelastine nasal spray also was significantly more effective than mometasone at each time point. Conclusion Azelastine nasal spray has a rapid (15 minute) onset of action. Azelastine nasal spray was superior to both placebo and mometasone nasal spray in reducing nasal symptoms of SAR occurring within 8 hours after an allergen challenge.

scholarly journals Efektivitas salin hipertonik terhadap waktu transpor mukosiliar dan skor gejala hidung penderita rinitis alergi

2018 ◽  
Vol 47 (2) ◽  
pp. 123
Author(s):  
Woro Safitri ◽  
Dwi Reno Pawarti ◽  
Titiek Hidayati Ahadiah
Keyword(s):  
Clinical Trial ◽  
Allergic Rhinitis ◽  
Symptom Score ◽  
Saline Group ◽  
Nasal Symptom ◽  
Control Group ◽  
Mucociliary Transport ◽  
Transport Time ◽  
Total Nasal Symptom Score ◽  
The Mean

Latar belakang: Rinitis alergi (RA) adalah suatu penyakit inflamasi mukosa hidung yang diperantara oleh imunoglobulin E (IgE), setelah mukosa hidung terpapar alergen. Tujuan: Mengidentifikasi efektivitas cuci hidung salin hipertonik terhadap waktu transpor mukosiliar dan skor gejala hidung total (SGHT) pada penderita RA. Metode: Penelitian dilaksanakan pada bulan Juli hingga Desember 2016 di Poli Telinga Hidung Tenggorok – Bedah Kepala Leher Rumah Sakit Dr. Soetomo Surabaya. Uji klinis acak terkontrol pada 2 kelompok dengan desain control group in clinical trial. Pengambilan sampel dilakukan secara consecutive sampling. Uji korelasi yang digunakan adalah uji t berpasangan dan uji Wilcoxon. Hasil: Didapatkan sampel 42 penderita, yaitu 21 penderita pada kelompok loratadin, serta 21 penderita pada kelompok loratadin dan cuci hidung salin hipertonik. Didapatkan rerata penurunan transpor mukosiliar kelompok loratadin dan cuci hidung salin hipertonik lebih bermakna daripada kelompok loratadin (p=0,001). Penurunan transpor mukosiliar kelompok loratadin didapatkan rerata -2,30 (SD=2,77), kelompok loratadin dan cuci hidung salin hipertonik didapatkan rerata -6,27 (SD=3,91). Penurunan SGHT kelompok loratadin didapatkan rerata -2,48 (SD=1,72), sedangkan kelompok loratadin dan cuci hidung salin hipertonik didapatkan rerata -4,3 (SD=1,20). Kesimpulan: Penambahan cuci hidung salin hipertonik pada terapi loratadin lebih efektif dibandingkan terapi tunggal loratadin dalam menurunkan transpor mukosiliar dan SGHT pada penderita RA. Kata kunci: Loratadin, cuci hidung salin hipertonik, transpor mukosiliar, skor gejala hidung total, rinitis alergi ABSTRACT Background: Allergic rhinitis (AR) is a nasal mucous membrane inflamatory which mediated by Imunoglobulin E (IgE) after allergen exposure in nasal mucosa. Purpose: To identify the effectiveness of nasal hypertonic saline irrigation on reduction of mucociliary transport time (MCTT) and total nasal symptom score (TNSS) in AR patients. Methods: The was conducted from July until December 2016 in Oto Rhino Laryngology - Head and Neck Surgery of Dr. Soetomo Hospital Surabaya. The study was randomized controlled clinical trials on two groups, with the control group in clinical trial design. Paired t and Wilcoxon test was used as the correlation test. Results: There was 42 patients, 21 patients in loratadine group, and 21 patients in loratadine with hypertonic nasal saline group. The average of mucociliary transport time decrease of loratadine with hypertonic nasal saline group was more significant than loratadine group (p=0.001). The mean of decreasing mucociliary transport time in loratadine group was -2.30 (SD=2.77) and loratadine with hypertonic nasal saline group was -6.27 (SD=3.91). The mean of decreasing TNSS in loratadin group was -2.48 (SD=1.72), and loratadin with hypertonic nasal saline group was -4.3 (SD=1.20). Conclusions: The addition of hypertonic nasal saline in loratadine was more effective, compared to monotherapy of loratadine in decreasing mucociliary transport time and TNSS in patient with AR. Keywords: Loratadine, hypertonic nasal saline, mucociliary transport, total nasal symptom score, allergic rhinitis

scholarly journals Investigation of the effectiveness of the drug «Glenspray active» in patients with allergic rhinitis

2019 ◽  
pp. 49-53
Author(s):  
Vladimir Bereznyuk ◽  
Alexander Chernokur
Keyword(s):  
Allergic Rhinitis ◽  
Epidemiological Studies ◽  
Nasal Symptom ◽  
Maximum Effect ◽  
Symptom Scale ◽  
The Past ◽  
Nasal Symptoms ◽  
Total Nasal Symptom Score ◽  
Number Of Patients ◽  
Effect Of Therapy

Relevance: Over the past decade, an increase in the number of patients with AR has been noted. According to epidemiological studies conducted in different countries, the prevalence of AR is from 1 to 40%. In most European countries, 10-25% of the population suffers from allergic rhinitis. Of particular interest for treatment are combination preparations containing topical corticosteroids and antihistamines, in particular, Glenspray Active. The active ingredients of the drug are mometasone furoate and azelastine hydrochloride. The purpose: study of effectiveness of the drug «Glenspray Active» usage in patients with allergic rhinitis. Results and discussion: 69 patients with allergic rhinitis were treated in the clinic of the SE «DMA of HM of Ukraine». In 61 patients intermittent AR was diagnosed, in 8 patients - persistent AR. Efficiency criteria were an assessment of the effect of therapy with the studied drug on the nasal symptoms of allergic rhinitis. To analyze the indicators, a general nasal symptom scale (TNSS – Total Nasal Symptom Score) was used, and the overall effectiveness of treatment by the patient and the research doctor was also evaluated. Most of patients (49-57%) noted a good and excellent effect from the use of the drug which occurred already between 30 and 60 minutes after the start of treatment. 85.5% of patients noted the maximum effect of the using of the drug which was between 30 and 60 minutes. Conclusion: The combined drug «Glenspray Active» is an effective and safe tool in the treatment of patients with AR. A good and excellent clinical effect in the form of a significant reduction in nasal symptoms (TNSS) occurs from 30 to 60 minutes in 44-57% of patients. The maximum effect from the use of the drug was observed between 30 and 60 minutes in 85.5% of patients.

Sign in / Sign up

Export Citation Format

Share Document